Market Cap
US$632.9m
Last Updated
2020/10/29 00:27 UTC
Data Sources
Company Financials +
Executive Summary
Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. More Details
Rewards
Risk Analysis
Snowflake Analysis
Flawless balance sheet with reasonable growth potential.
Similar Companies
Share Price & News
How has Inogen's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: INGN has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
0.9%
INGN
-3.6%
US Medical Equipment
-4.6%
US Market
1 Year Return
-47.3%
INGN
16.8%
US Medical Equipment
11.5%
US Market
Return vs Industry: INGN underperformed the US Medical Equipment industry which returned 16.8% over the past year.
Return vs Market: INGN underperformed the US Market which returned 11.5% over the past year.
Shareholder returns
| INGN | Industry | Market | |
|---|---|---|---|
| 7 Day | 0.9% | -3.6% | -4.6% |
| 30 Day | -1.6% | 1.4% | -0.9% |
| 90 Day | -6.6% | 1.8% | 2.2% |
| 1 Year | -47.3%-47.3% | 17.8%16.8% | 14.0%11.5% |
| 3 Year | -70.7%-70.7% | 70.9%66.4% | 34.5%25.6% |
| 5 Year | -38.6%-38.6% | 128.9%111.0% | 73.0%53.6% |
Price Volatility Vs. Market
How volatile is Inogen's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 days ago | Simply Wall St
Are Inogen's (NASDAQ:INGN) Statutory Earnings A Good Guide To Its Underlying Profitability?1 month ago | Simply Wall St
Inogen's(NASDAQ:INGN) Share Price Is Down 70% Over The Past Three Years.1 month ago | Simply Wall St
Inogen, Inc. (NASDAQ:INGN) Shares Could Be 21% Above Their Intrinsic Value EstimateValuation
Is Inogen undervalued compared to its fair value and its price relative to the market?
96.94x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: INGN ($28.68) is trading above our estimate of fair value ($26.21)
Significantly Below Fair Value: INGN is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: INGN is poor value based on its PE Ratio (96.9x) compared to the US Medical Equipment industry average (53.2x).
PE vs Market: INGN is poor value based on its PE Ratio (96.9x) compared to the US market (18.1x).
Price to Earnings Growth Ratio
PEG Ratio: INGN is poor value based on its PEG Ratio (1.6x)
Price to Book Ratio
PB vs Industry: INGN is good value based on its PB Ratio (1.8x) compared to the US Medical Equipment industry average (3.8x).
Next Steps
Future Growth
How is Inogen forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
59.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: INGN's forecast earnings growth (59.4% per year) is above the savings rate (2.2%).
Earnings vs Market: INGN's earnings (59.4% per year) are forecast to grow faster than the US market (22% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: INGN's revenue (10.5% per year) is forecast to grow faster than the US market (10% per year).
High Growth Revenue: INGN's revenue (10.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: INGN's Return on Equity is forecast to be low in 3 years time (1.6%).
Next Steps
Past Performance
How has Inogen performed over the past 5 years?
15.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: INGN has a large one-off gain of $5.4M impacting its June 30 2020 financial results.
Growing Profit Margin: INGN's current net profit margins (2%) are lower than last year (11.2%).
Past Earnings Growth Analysis
Earnings Trend: INGN's earnings have grown by 15.4% per year over the past 5 years.
Accelerating Growth: INGN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: INGN had negative earnings growth (-84.5%) over the past year, making it difficult to compare to the Medical Equipment industry average (1.9%).
Return on Equity
High ROE: INGN's Return on Equity (1.8%) is considered low.
Next Steps
Financial Health
How is Inogen's financial position?
Financial Position Analysis
Short Term Liabilities: INGN's short term assets ($302.8M) exceed its short term liabilities ($50.6M).
Long Term Liabilities: INGN's short term assets ($302.8M) exceed its long term liabilities ($56.4M).
Debt to Equity History and Analysis
Debt Level: INGN is debt free.
Reducing Debt: INGN has no debt compared to 5 years ago when its debt to equity ratio was 0.4%.
Debt Coverage: INGN has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: INGN has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Next Steps
Dividend
What is Inogen current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate INGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate INGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if INGN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if INGN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of INGN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
11.7yrs
Average management tenure
CEO
Scott Wilkinson (55 yo)
3.58yrs
Tenure
US$2,520,530
Compensation
Mr. Scott Wilkinson has been the Chief Executive Officer of Inogen, Inc. since March 1, 2017 and as its President since January 1, 2016. Mr. Wilkinson served as the Chief Operating Officer of Inogen, Inc. ...
CEO Compensation Analysis
Compensation vs Market: Scott's total compensation ($USD2.52M) is about average for companies of similar size in the US market ($USD3.00M).
Compensation vs Earnings: Scott's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 3.58yrs | US$2.52m | 0.14% $ 905.2k | |
| Co-founder & Executive VP of Engineering | 19.75yrs | US$845.76k | 0.26% $ 1.7m | |
| Co-founder | 19.75yrs | US$1.17m | 0.15% $ 933.9k | |
| Founder & Executive Vice President of Marketing | 19.75yrs | US$876.82k | 0.17% $ 1.1m | |
| Executive Vice President of Operations | 2.08yrs | US$1.07m | 0.020% $ 125.6k | |
| Investor Relations & Corporate Development Manager | no data | no data | no data | |
| Executive Vice President of Sales | 0.17yr | no data | no data | |
| Investor Relations Officer | no data | no data | no data |
11.7yrs
Average Tenure
41yo
Average Age
Experienced Management: INGN's management team is seasoned and experienced (11.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 3.58yrs | US$2.52m | 0.14% $ 905.2k | |
| Independent Director | 7.75yrs | US$235.02k | 0.036% $ 229.3k | |
| Independent Director | 5.17yrs | US$245.02k | 0.081% $ 515.3k | |
| Director | 12.75yrs | US$225.02k | 0.047% $ 295.1k | |
| Independent Chairman of the Board | 12.75yrs | US$310.02k | 0.025% $ 157.2k | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Independent Director | 7.75yrs | US$235.02k | 0.020% $ 128.5k | |
| Member of Advisory Board | no data | no data | no data | |
| Independent Director | 6.17yrs | US$245.02k | 0.029% $ 185.9k |
7.8yrs
Average Tenure
61yo
Average Age
Experienced Board: INGN's board of directors are considered experienced (7.8 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Inogen, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Inogen, Inc.
- Ticker: INGN
- Exchange: NasdaqGS
- Founded: 2001
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$632.854m
- Shares outstanding: 22.07m
- Website: https://www.inogen.com
Number of Employees
Location
- Inogen, Inc.
- 326 Bollay Drive
- Goleta
- California
- 93117
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| INGN | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Feb 2014 |
| 6IO | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Feb 2014 |
Biography
Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United S ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/10/29 00:27 |
| End of Day Share Price | 2020/10/28 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.